Crispr Therapeutics AG vs Kaltura Inc — how do they compare? Crispr Therapeutics AG trades at $53.96 (market cap $5.23B), while Kaltura Inc trades at $1.63 (market cap $249.42M). The key difference: Crispr Therapeutics AG is far larger — about 21× Kaltura Inc's market cap, and Kaltura Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | KLTR | |
|---|---|---|
Market Cap | $5.23B | $249.42M |
Sector | Health | Technology |
52-Week High | $76.78 | $1.89 |
52-Week Low | $44.34 | $1.08 |
Enterprise Value | $3.65B | $261.64M |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →